Providian Financial Warns of a Weaker Fourth Quarter
Quest Diagnostics (DGX ) posted $0.51 vs. $0.30 Q3 EPS on a 6.2% revenue rise. UBS Warburg raised estimates.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.